Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

88/433 Matches for
“HIV non-alcoholic fatty liver disease”

“HIV non-alcoholic fatty liver disease” Clear all

  1. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 100

    …HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver disease…

    FibroTest NashTest SteatoTest HIV

  2. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 100

    FibroTest Metabolic

  3. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 99

    …been studied in HIV-infected individuals. Non-invasive liver fibrosis tools include…

    FibroTest HBV HCV HIV

  4. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 99

    ActiTest AshTest FibroTest NashTest +6

  5. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 98

    …of liver morbidity and mortality in non-alcoholic fatty liver disease (NAFLD…

    FibroTest Metabolic

  6. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 98

    …developing complications of end-stage liver disease. Although it lacks sensitivity, ultrasonography…

    ActiTest FibroTest NashTest SteatoTest +1

  7. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 97

    …B virus, nonalcoholic fatty liver disease, alcoholic liver disease, or cholestatic diseases…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  8. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 97

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  9. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 96

    …and quantification in nonalcoholic fatty liver disease (NAFLD). ### Methods Cross-sectional study…

    SteatoTest Metabolic

  10. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 95

    FibroTest Alcohol HBV HCV +3

  11. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 95

    …CAP was significantly correlated with SteatoTest, Fatty Liver Index (FLI), percentage of…

    SteatoTest Metabolic

  12. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 94

    …liver disease (59.6%) and chronic hepatitis B (52.9%). Liver biopsy…

    FibroTest Alcohol HBV HCV +3

  13. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 94

    …The rate of adoption of non-invasive diagnostic tests for liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  14. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 93

    …standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The…

    FibroTest Metabolic

  15. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 93

    …assessment of non-alcoholic fatty liver disease (NAFLD). Since liver biopsy is…

    FibroTest Metabolic

  16. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 92

    …non-alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver…

    FibroTest Alcohol HBV HCV +1

  17. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 91

    …ELF, ≥10.43; Nonalcoholic Fatty Liver Disease Fibrosis Score, ≥1.80; Fibrotest…

    FibroTest Metabolic

  18. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 91

    …of fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar…

    FibroTest Alcohol HBV HCV +1

  19. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 90

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  20. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 90

    …liver disease, hepatitis C, hepatitis B, and alcoholic or non alcoholic fatty…

    FibroTest Alcohol HBV HCV +3

  21. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 89

    …liver disease, hepatitis C, hepatitis B, alcoholic or nonalcoholic fatty liver disease…

    ActiTest FibroTest SteatoTest Alcohol +5

  22. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 89

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  23. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 88

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  24. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 87

    …The assessment of the degree of liver fibrosis in alcoholic liver disease…

    FibroTest Alcohol

  25. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 87

    …CHB and its consequences on liver injury compared with CHC and NAFLD…

    FibroTest SteatoTest HBV HCV +1

  26. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 86

    …of liver affection, and analyse the influence of the HIV disease severity…

    FibroTest HIV

  27. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 86

    …fibrosis were both alcoholic and nonalcoholic fatty liver disease (NAFLD) in 66…

    FibroTest Alcohol HBV HCV +3

  28. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 85

    …with non-alcoholic fatty liver disease, NashTest, a simple and non-invasive…

    NashTest Metabolic

  29. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 85

    …In HBV and non-alcoholic steatohepatitis (NASH) patients, its performance was poor…

    FibroTest HBV HCV HIV +1

  30. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 84

    …Utility of non-invasive markers of liver fibrosis has been proved in…

    FibroTest

  31. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 83

    …CHB), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD…

    FibroTest Alcohol HBV HCV +2

  32. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 83

    …the prediction of non-alcoholic liver disease by non-invasive blood tests…

    FibroTest NashTest-2 SteatoTest Metabolic

  33. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 82

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  34. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 82

    …1.97% in P4, 1.77% in HIV centre and 2.61…

    ActiTest FibroTest Alcohol HBV +4

  35. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 81

    …Steatosis was demonstrated in all 5 patients who received liver biopsies during…

    FibroTest Other

  36. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 81

    …fibrosis in patients with alcoholic liver disease recruited from primary and secondary…

    FibroTest Alcohol

  37. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 80

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  38. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 79

    …The best marker of liver fibrosis in alcoholic patients seems to be…

    FibroTest Alcohol

  39. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 79

    …chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty…

    FibroTest Alcohol HBV HCV +1

  40. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 78

    …the interpretation of non-invasive biomarkers in liver fibrosis. A scoring system…

    ActiTest FibroTest SteatoTest Alcohol +5

  41. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 78

    …elderly patients without liver disease (group A, 85.2+/-7.3 years…

    FibroTest

  42. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 77

    FibroTest Alcohol

  43. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 77

    …SVR benefits are well-recognized with reductions in rates of liver complications…

    FibroTest HCV

  44. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 76

    …factors for liver disease should be closely monitored with non-invasive methods…

    FibroTest Other

  45. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 75

    …97 with alcoholic liver disease (ALD), and 223 non-ALD, were included…

    FibroTest SteatoTest Alcohol

  46. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 75

    ActiTest FibroTest Alcohol HBV +3

  47. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 74

    …Conclusions In patients with chronic liver disease the LCR1 and LCR2 tests…

    LCR1 LCR2 Alcohol HBV +4

  48. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 74

    …Liver biopsy, because of its limitations and risks, might be considered an…

    ActiTest FibroTest HCV

  49. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 73

    …Non-invasive techniques, liver stiffness measurements (LSM) and biomarkers [FibroTest(R) (FT…

    FibroTest Alcohol HBV HCV +3

  50. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 73

    ActiTest FibroTest HCV

  51. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.

    Adler M et al. · Hepatology · 2008 Match 72

    FibroTest Alcohol HBV HCV +1

  52. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 72

    FibroTest Alcohol HBV HCV +1

  53. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.

    Terrier B et al. · J Hepatol · 2011 Match 71

    …Data are lacking in HIV-HCV coinfected patients. ### Methods One hundred and…

    ActiTest FibroTest HCV HIV

  54. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 70

    …values for use in alcoholic liver disease (ALD). The aims of this…

    FibroTest Alcohol

  55. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 70

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver…

    FibroTest HCV

  56. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 69

    …in order to avoid the liver biopsy currently used for selection of…

    FibroTest HCV

  57. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 69

    FibroTest HCV

  58. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 68

    …depending on etiology and disease stage. Liver biopsy, traditionally regarded as the…

    FibroTest HCV

  59. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 68

    …To evaluate the association between anthropometric measurements and advanced liver disease in…

    ActiTest FibroTest HCV

  60. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 67

    …and ninety patients with chronic liver disease of miscellaneous causes were included…

    FibroTest Alcohol HBV HCV +2

  61. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 66

    …Aims To assess Fibroscan for non-invasive diagnosis of asymptomatic liver fibrosis…

    FibroTest Alcohol

  62. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 66

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  63. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 65

    …liver disease severity. ### Objective To compare the awareness of liver disease severity…

    ActiTest FibroTest Alcohol HBV +3

  64. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 65

    …various aspects of liver fibrosis relevant to disease patterns and clinical practice…

    FibroTest SteatoTest HBV HCV +1

  65. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 64

    …alcoholic steato-hepatitis (ASH), in patients with chronic alcoholic liver disease. ### Methods…

    AshTest Alcohol

  66. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 64

    …the early spread of coronavirus disease 2019 (Covid-19) in the general…

    FibroTest COVID

  67. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 63

    …The reliance on invasive liver biopsy to stage disease is diminishing with…

    FibroTest HBV

  68. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 62

    …liver histological stages, an assessment of the disease development based on non…

    FibroTest HCV

  69. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 62

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  70. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 61

    …liver disease. Thus, we systematically evaluated the potential utility of several non…

    ActiTest FibroTest Other

  71. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 61

    …virus (HCV) infection or non-HCV-related liver diseases. ### Methods And Results…

    FibroTest Alcohol HBV HCV +2

  72. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 60

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  73. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 60

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver…

    FibroTest Other

  74. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 59

    …fibrosis in patients with chronic liver disease. This paper aims to assess…

    FibroTest Alcohol HBV HCV +3

  75. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 58

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  76. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 58

    FibroTest HBV

  77. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 57

    ### Background Liver stiffness and non-invasive tests predict overall survival in chronic…

    FibroTest HBV

  78. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 57

    …These consisted of 29 healthy volunteers and 35 patients with chronic liver…

    ActiTest FibroTest Alcohol HBV +3

  79. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 56

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  80. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 56

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  81. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 55

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  82. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 54

    …including hepatic necroinflammatory activity, on liver stiffness measurement (LSM). This prospective study…

    FibroTest HCV

  83. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 54

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  84. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 53

    …enrolled 103 patients for whom liver biopsy, hepatic elastography results, and laboratory…

    ActiTest FibroTest AIH

  85. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 53

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  86. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 52

    ActiTest FibroTest HBV

  87. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 52

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  88. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.